Nasal polyps trial tests stretching biologic doses
NCT ID NCT07187583
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study looks at whether people with chronic nasal polyps who are stable on biologic drugs like dupilumab or mepolizumab can safely extend the time between doses from every 4 weeks to every 6 or 8 weeks. The goal is to see if symptom control can be maintained with fewer injections. 135 adults who have been on a steady dose for at least three months will participate.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
biologic drugs (dupilumab or mepolizumab)
What this could lead to
If successful, this could allow patients with chronic nasal polyps to take their medication less often while still controlling symptoms, reducing treatment burden and side effects.
What could go wrong
This is a Phase 4 trial with only 135 participants, so results may not apply to everyone. Some patients might lose disease control with longer dosing intervals, requiring a return to the original schedule.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC RHINOSINUSITIS WITH NASAL POLYPS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Otorhinolaryngology, Head and Neck Surgery & Audiology, Copenhagen University, Rigshospitalet
RECRUITINGCopenhagen, 2100, Denmark
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
-
Dept of otorhinolaryngology, Aalborg University Hospital
NOT_YET_RECRUITINGAalborg, 9000, Denmark
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Dept of otorhinolaryngology, Gødstrup Regional Hospital
NOT_YET_RECRUITINGHerning, 7400, Denmark
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Dept of otorhinolaryngology, Lillebaelt Hospital
NOT_YET_RECRUITINGVejle, 7100, Denmark
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Dept of otorhinolaryngology, Nordsjaellands Hospital
RECRUITINGHillerød, 3400, Denmark
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Dept of otorhinolaryngology, Odense University Hospital
NOT_YET_RECRUITINGOdense, 5000, Denmark
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Dept of otorhinolaryngology, Sjællands Universitetshospital
RECRUITINGKøge, 4600, Denmark
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Dept of otorhinolaryngology, head and neck surgery, Aarhus University Hospital
NOT_YET_RECRUITINGAarhus, 8200, Denmark
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Esbjerg Og Grindsted Sygehus
NOT_YET_RECRUITINGEsbjerg, 6700, Denmark
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact